when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

2,180 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT1032 Endpoints784 BioPharma Dive299 BioSpace219 Fierce Biotech207 onclive165 raps78 globenewswire health

therapy area

all Oncology6093 Rare Disease1466 Cardiology1094 Hematology1031 Immunology1014 Vaccines918 Pulmonology

Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook
The cruise ship hantavirus outbreak is serious but limited. Online, it's another story.
STAT · 3mo ago↗ source
Giants of Cancer Care Announces the 14th Annual Class of Inductees
onclive · 3mo ago↗ source
OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
onclive · 3mo ago↗ source

page 74 of 88

73

911

Psychiatry & CNS724

Ophthalmology424

Endocrinology & Metabolism387

Infectious Disease361

Former FDA leaders, pharma speak out on mifepristone

“The fundamental question is: Who gets to regulate mifepristone?”

STAT · 3mo ago↗ source

FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering

🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...

Endpoints · 3mo ago↗ source

STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

STAT · 3mo ago↗ source

The biotechs wear Prada

Was Naomi Osaka's Met Gala outfit inspired by Gilead's logo? Janelle Monáe's by Insilico's? Probably not — and yet.

STAT · 3mo ago↗ source

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026

Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

onclive · 3mo ago↗ source

Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

onclive · 3mo ago↗ source

STAT+: The biotech news you need to read today

A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout

STAT · 3mo ago↗ source

STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more

An FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on research

STAT · 3mo ago↗ source

'Pharma, not really’: Top young AI talent shuns careers at big drugmakers

RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medical…

Endpoints · 3mo ago↗ source

Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.

onclive · 3mo ago↗ source

The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer

Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patien…

onclive · 3mo ago↗ source

Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study

This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequ…

onclive · 3mo ago↗ source

First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

onclive · 3mo ago↗ source

Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability

This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies…

onclive · 3mo ago↗ source

The aging scientific workforce collides with rising fabricating citations in medical journals

The latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning Rounds

STAT · 3mo ago↗ source

Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech

→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of ...

Endpoints · 3mo ago↗ source

Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep

Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…

Endpoints · 3mo ago↗ source

Opinion: We need more men in nursing

Men make up just 12% of nurses nationally. That needs to change.

STAT · 3mo ago↗ source

Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting

“The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian.

STAT · 3mo ago↗ source

Why we left the FDA: Six former officials share their stories

In this week's STATus Report, hear from six former FDA officials on why they left the agency.

STAT · 3mo ago↗ source

Odyssey raises more than $300M as biotech goes public

Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The bio…

Endpoints · 3mo ago↗ source

Dr Sznol on Optimal Treatment Sequencing in Melanoma

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

onclive · 3mo ago↗ source